<DOC>
	<DOCNO>NCT01079325</DOCNO>
	<brief_summary>The purpose study evaluate clinical effect investigational drug , SB-509 , subject diabetic neuropathy .</brief_summary>
	<brief_title>Clinical Trial SB-509 Subjects With Diabetic Neuropathy</brief_title>
	<detailed_description>SB-509 contains gene ( DNA—a kind biological `` blueprint '' ) protein . When researcher inject SB-509 leg , drug enters muscle nerve cell around injection site cause cell make protein . This protein cause cell increase production another protein call vascular endothelial growth factor ( VEGF ) , may improve structure function nerve . In addition , change level additional protein cell . These protein function promote growth cell , structure cell , help synthesize product , affect immune cell , unknown function . This increase VEGF proteins may protect repair damaged nerve cause diabetic neuropathy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Key Clinical diagnosis Diabetes Mellitus Type I II least 12 month Clinical sign symptom moderate severe diabetic sensorymotor polyneuropathy low extremity least 6 month otherwise attribute etiology diabetes Measurable sural peroneal response bilaterally HgbA1C level ≤ 10 % LDL cholesterol ≤ 160 mg/dL Blood pressure ≤ 140/90 mm Hg Body mass index ( BMI ) ≤ 38 Key Moderate severe ischemic heart disease history congestive heart failure , myocardial infarction within previous 6 month Evidence cardiac enlargement and/or congestive heart failure Current diabetic foot leg ulcer , gangrene low extremity , amputation lower extremity History malignancy , except follow : adequately treat basal cell squamous cell skin cancer , superficial bladder cancer , adequately treat Stage 1 2 cancer currently complete remission , cancer complete remission least 5 year Immune immunodeficiency disorder expect require immunosuppressant 30 day prior , , 30 day follow administration investigational drug product History current proliferative retinopathy , macular edema retinal neovascularization Precancerous condition benign tumor potential clinically significant growth due VEGF stimulation Family history inherit neuropathy ( e.g . Charcot Marie Tooth , Hereditary Predisposition Pressure Palsy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Diabetic neuropathy</keyword>
	<keyword>Diabetes Type 1 2</keyword>
	<keyword>Moderately severe sensorimotor diabetic polyneuropathy</keyword>
</DOC>